Thursday's review by the Central Pharmaceutical Advisory Committee is the second of three reviews.
"We went through the data of Janssen's COVID-19 vaccine and discussed its safety and efficacy. After consideration, we saw its preventive effect and we advise the authorization of this vaccine."
Based on the clinical data, the review panel has confirmed that for people over the age of 18, the prevention effect 14 and 28 days after one shot was both over 66 percent.
That's above the 50 percent prevention effect that the World Health Organization has set.
The panel of experts says it's safe as the adverse reactions were within the safe boundary.